Abstract: A display panel and a display device are provided. The display panel includes a display region and a non-display region. The non-display region includes a demultiplexing circuit, a fanout wire, and a clock signal line. An input terminal of the demultiplexing circuit is electrically connected to the fanout wire, an output terminal of the demultiplexing circuit is electrically connected to a data line in the display region, and a control terminal of the demultiplexing circuit is electrically connected to the clock signal line. The display panel further includes an isolation signal line including an isolation portion, and an orthographic projection of the isolation portion on a plane where a substrate is located is between an orthographic projection of the clock signal line on the plane where the substrate is located and an orthographic projection of the fanout wire on the plane where the substrate is located.

Abstract: A structure of a two-dimensional material-based device having an air-gap and a method for preparing same comprises a substrate, a gate, an dielectric, a two-dimensional material-based film, and source and drain electrodes; the air-gap is formed between the two-dimensional material-based film and the side wall of the dielectric on the gate, or the air-gap is formed between the dielectric and the gate; two-dimensional material-based devices of the above structure utilize the ductility and flexibility of two-dimensional materials to reduce the coupling between the gate and the source/drain electrodes, thereby reducing the parasitic capacitance and the circuit delay; also, the structure ensures that a part of the contact region of the source and drain electrodes with the two-dimensional material can be controlled by the gate, and can thus avoid the reduction in electrical properties and keep a low resistance of the device.

Abstract: The invention provides an immunogenic composition for preventing pneumococcal diseases, comprising PspA-MRX1, PspA-EF5668, PspA-EF3296 and PlyL460D, wherein the amount of each component is 10-100 ?g/ml; the immunogenic composition is prepared by adding to aluminum adjuvant the corresponding dosages of the four stock solutions PspA-mRX1, PspA-EF5668, PspA-EF3296 and PlyL460D, and mixing them homogeneously; the immunogenic composition can prevent infection and invasion by Streptococcus pneumonia, covering more than 95% of the strains in clinic. The immunogenic composition has a wide application in the prevention of pneumonia, and is suitable for large-scale production in industry for its simple preparation method, low production cost, and short production cycle.

Abstract: The invention provides an immunogenic composition for preventing pneumococcal diseases, comprising PspA-MRXI, PspA-EF5668, PspA-EF3296 and PlyL460D, wherein the amount of each component is 10-100 ?g/ml; the immunogenic composition is prepared by adding to aluminum adjuvant the corresponding dosages of the four stock solutions PspA-mRXI, PspA-EF5668, PspA-EF3296 and PlyL460D, and mixing them homogeneously; the immunogenic composition can prevent infection and invasion by Streptococcus pneumonia, covering more than 95% of the strains in clinic. The immunogenic composition has a wide application in the prevention of pneumonia, and is suitable for large-scale production in industry for its simple preparation method, low production cost, and short production cycle.

Abstract: Randomly generated glycopeptide combinatorial libraries are generated by randomly glycosylating a peptide having at least one glycosylation site with at least one glycosyl donor, optionally blocking unreacted glycosylation sites on the glycopeptides and optionally selectively removing one or more protecting groups on the carbohydrate groups introduced at the first level; whereby a first level library of glycopeptides is created; and then optionally randomly glycosylating said first level library of glycopeptides, or a combination of first level libraries of glycopeptides, with at least one glycosyl donor, and optionally selectively removing one or more designated protecting groups on the carbohydrate groups introduced at the second level; whereby a second level library of glycopeptides is created. Further iterations of the process result in higher level libraries of increased diversity. The glycopeptide libraries including, e.g.